FGFR2 and cholangiocarcinoma: Other frequently observed fusions were EML4-ALK (1% of lung adenocarcinomas), CCDC6-RET (4.2% of thyroid cancers), and FGFR2-BICC1 (5.6% of cholangiocarcinoma cases).41 Analysis of 8,984 and 17,485 tumors in the TCGA and MSK-IMPACT datasets, respectively, identified NRG1 fusions with novel partners in multiple cancer types, including breast, head and neck, lung, ovarian, pancreatic, prostate, renal, and uterine cancers.82 These large-scale investigations highlight key disease areas (NSCLC, glioma, BTC, and thyroid and pancreatic cancers) and relevant—potentially actionable—fusions.